Baseline characteristics
| Characteristic . | Value . |
|---|---|
| Total | 105 (100%) |
| Age at enrollment, y | 54 (22,76) |
| Time from HSCT to study entry, y | 2.7 (0.5, 12.1) |
| Time from cGVHD to study entry, y | 1.7 (0.1, 11.8) |
| No. of prior treatments | 3 (1, 9) |
| No. of sites involved | 4 (1, 7) |
| Global score at enrollment | 6 (2, 10) |
| Sex | |
| Female | 41 (39%) |
| Male | 64 (61%) |
| ECOG PS at study enrollment | |
| 0 | 6 (5.7%) |
| 1 | 69 (65.7%) |
| 2 | 28 (26.7%) |
| UNK | 2 (1.9%) |
| HLA typing (A,B,C, DRB1) | |
| Matched, related | 32 (30.5%) |
| Matched, unrelated | 63 (60%) |
| Mismatch, unrelated | 10 (9.5%) |
| Progenitor cell source | |
| BM | 5 (4.8%) |
| BM and PBSC | 1 (1%) |
| PBSC | 98 (93.3%) |
| UNK | 1 (1%) |
| Primary disease | |
| ALL | 8 (7.6%) |
| AML | 31 (29.5%) |
| CLL/SLL/PLL | 12 (11.4%) |
| CML | 5 (4.8%) |
| Hodgkin disease | 2 (1.9%) |
| MDS | 20 (19%) |
| MPD | 4 (3.8%) |
| Mixed MDS/MPD | 1 (1%) |
| Multiple myeloma | 2 (1.9%) |
| Non–Hodgkin lymphoma | 18 (17.1%) |
| Other acute leukemia | 1 (1%) |
| Other | 1 (1%) |
| Conditioning intensity | |
| Myeloablative | 55 (52.4%) |
| Non-myeloablative | 49 (46.7%) |
| UNK | 1 (1%) |
| Prior acute GVHD | |
| None | 58 (55.2%) |
| I | 15 (14.3%) |
| II | 24 (22.9%) |
| III | 8 (7.6%) |
| cGVHD severity at study enrollment | |
| Mild | 9 (8.6%) |
| Moderate | 63 (60%) |
| Severe | 33 (31.4%) |
| Characteristic . | Value . |
|---|---|
| Total | 105 (100%) |
| Age at enrollment, y | 54 (22,76) |
| Time from HSCT to study entry, y | 2.7 (0.5, 12.1) |
| Time from cGVHD to study entry, y | 1.7 (0.1, 11.8) |
| No. of prior treatments | 3 (1, 9) |
| No. of sites involved | 4 (1, 7) |
| Global score at enrollment | 6 (2, 10) |
| Sex | |
| Female | 41 (39%) |
| Male | 64 (61%) |
| ECOG PS at study enrollment | |
| 0 | 6 (5.7%) |
| 1 | 69 (65.7%) |
| 2 | 28 (26.7%) |
| UNK | 2 (1.9%) |
| HLA typing (A,B,C, DRB1) | |
| Matched, related | 32 (30.5%) |
| Matched, unrelated | 63 (60%) |
| Mismatch, unrelated | 10 (9.5%) |
| Progenitor cell source | |
| BM | 5 (4.8%) |
| BM and PBSC | 1 (1%) |
| PBSC | 98 (93.3%) |
| UNK | 1 (1%) |
| Primary disease | |
| ALL | 8 (7.6%) |
| AML | 31 (29.5%) |
| CLL/SLL/PLL | 12 (11.4%) |
| CML | 5 (4.8%) |
| Hodgkin disease | 2 (1.9%) |
| MDS | 20 (19%) |
| MPD | 4 (3.8%) |
| Mixed MDS/MPD | 1 (1%) |
| Multiple myeloma | 2 (1.9%) |
| Non–Hodgkin lymphoma | 18 (17.1%) |
| Other acute leukemia | 1 (1%) |
| Other | 1 (1%) |
| Conditioning intensity | |
| Myeloablative | 55 (52.4%) |
| Non-myeloablative | 49 (46.7%) |
| UNK | 1 (1%) |
| Prior acute GVHD | |
| None | 58 (55.2%) |
| I | 15 (14.3%) |
| II | 24 (22.9%) |
| III | 8 (7.6%) |
| cGVHD severity at study enrollment | |
| Mild | 9 (8.6%) |
| Moderate | 63 (60%) |
| Severe | 33 (31.4%) |
Data are presented as median (range) for continuous variables and frequency (%) for categorical variables.
AML, acute myeloid leukemia; BM, bone marrow; CLL/SLL/PLL, chronic lymphocytic leukemia/small lymphocytic lymphoma/prolymphocytic leukemia; ECOG PS, Eastern Cooperative Oncology Group performance status; HSCT, hematopoietic stem cell transplantation; MDS, myelodysplastic syndrome; MPD, myeloproliferative disorder; PBSC, peripheral blood stem cell; UNK, unknown.